Vedolizumab for children with chronic pouchitis
Treatments studied
Part of Digestive system clinical trials.
This study tests a medicine called vedolizumab to see if it is safe and helps children and teenagers with chronic pouchitis (inflammation in the pouch after colon removal). It is for kids who have not had good results with other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Weighs at least 10 kg (about 22 pounds).
- Is between 2 and 17 years old.
- Has had surgery to remove the colon and create an internal pouch (J-pouch) at least one year ago.
- Has active pouch inflammation (pouchitis) with symptoms and a scope showing inflammation.
- Has tried antibiotics or other treatments for pouchitis that didn't work or caused problems.
- Does not have certain infections or other conditions that would make the study unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a medication called guselkumab to antibiotics can help people with chronic or recurring pouchitis, a condition that causes inflammation in the J-pouch after ulcerative colitis surgery. Participants will take antibiotics for the first 4 weeks and guselkumab as an injection over the course of the trial.
This trial tests if etrasimod can prevent pouchitis, which is inflammation of the surgically created internal pouch, in people who have had their colon removed due to ulcerative colitis. If you are at high risk for pouchitis or have had only one episode, this study may help keep your pouch healthy.
This trial tests whether the antibiotic rifaximin can prevent pouchitis from coming back after a first episode. It is for people who had ulcerative colitis, have a J-pouch, and developed pouchitis within the first year after their final surgery.
This trial tests vedolizumab, a biologic medicine that reduces inflammation, in children and teenagers who have moderate to severe ulcerative colitis or Crohn's disease and have not responded well to other treatments.
This Phase 3 study tests whether vedolizumab can help children with ulcerative colitis (UC) or Crohn’s disease (CD) who improved on earlier treatment. It focuses on kids who can stay off steroid medicines and follow study visits and safety rules.
This study is for children and teenagers with ulcerative colitis or Crohn's disease who have already completed a previous vedolizumab study and are doing well. It will look at the long-term safety and effectiveness of continuing vedolizumab treatment.
Hear when a new Pouchitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.